APA (7th ed.) Citation

MS, T., H, E., A, F., A, H., T, W., J, W., . . . IS, L. (2023). Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma. Journal of cancer research and clinical oncology, 149(2), 811. https://doi.org/10.1007/s00432-021-03847-5

Chicago Style (17th ed.) Citation

MS, Topp, et al. "Anti-CD20-atezolizumab-polatuzumab Vedotin in Relapsed/refractory Follicular and Diffuse Large B-cell Lymphoma." Journal of Cancer Research and Clinical Oncology 149, no. 2 (2023): 811. https://doi.org/10.1007/s00432-021-03847-5.

MLA (9th ed.) Citation

MS, Topp, et al. "Anti-CD20-atezolizumab-polatuzumab Vedotin in Relapsed/refractory Follicular and Diffuse Large B-cell Lymphoma." Journal of Cancer Research and Clinical Oncology, vol. 149, no. 2, 2023, p. 811, https://doi.org/10.1007/s00432-021-03847-5.